In this issue: The long-awaited approval of a second long-acting injectable PrEP formulation — twice-yearly lenacapavir — has come. What are the most important things clinicians need to understand when considering prescribing this new agent?

How does Q6 months LA lenacapavir differ from already available LA cabotegravir? Which patients is appropriate for? What kinds of monitoring are required, both at treatment initiation and with every following injection? What are the predominant safety issues, and how should they be managed?

Join us as Matthew Spinelli, MD, MAS, Associate Professor of HIV, Infectious Disease, and Global Medicine at Zuckerberg San Francisco General Hospital, shares his experience and expertise in helping clinicians considering either of these LA PrEP options … in this issue of eHIV Review.

Hosted on Acast. See acast.com/privacy for more information.

In this issue we focus on youth: the 13 to 24-year-old population responsible for nearly 20% of new HIV diagnoses in the US. Their entry into the HIV care continuum has been slow, hindered by barriers that are just now beginning to be recognized and overcome. What’s been done, what’s being done, and what needs to be done to better educate and motivate this critically important under-diagnosed and under-treated community?

Join Dr. David C. Griffith from the Departments of Medicine and Pediatrics at the Johns Hopkins University School of Medicine in Baltimore, as he shares his knowledge and expertise in identifying and managing youth at risk for becoming infected, as well as those already living with, HIV — in this issue of eHIV Review.

Hosted on Acast. See acast.com/privacy for more information.

PWH. People living with HIV. They’re growing older. And they’re experiencing the same illnesses of aging — CVD, kidney and liver diseases, cancers — as their HIV-seronegative counterparts.

The question is: how should they be treated?

Should the comorbidities of aging PWH be managed with the same agents and dosing regimens as people the same age who have not been fighting a chronic infective condition? How do the treatments that have increased PWH wellness and expected lifespans affect the safety and efficacy of the preferred comorbidity management options? What does the evidence-based data say?

Join Dr. Maile Young Karris, Co-Director of the San Diego Center for AIDS Research Clinical Investigations Core, and an Associate Professor from the Department of Medicine at the University of California in San Diego, as we discuss strategies to mitigate the effects of comorbidities in older people living with HIV — in this issue of eHIV Review.

Hosted on Acast. See acast.com/privacy for more information.

PrEP. For most patients, that’s a simple drug regimen that can be prescribed after a negative HIV screen. Safe. Effective. Proactive protection to stop the spread of HIV infection in MSM, cisgender, and transgender individuals.

Post-test for CME credits: https://elit.dkbmed.com/issues/228/test

Hosted on Acast. See acast.com/privacy for more information.

How will the current research advancements in long-acting ART affect clinicians’ ability to provide better care for their patients with HIV? The recent data show that the low uptake and adherence to PrEP may be largely due to the pill burden and potential stigma of daily dosing. How might the newer longer-acting PrEP regimens challenge this reluctance?

Post-test for CME credits: https://elit.dkbmed.com/issues/226/test

Hosted on Acast. See acast.com/privacy for more information.

The primary health concern for all individuals living with HIV should be managing their disease, particularly maintaining adherence to their ART treatment. Yet for many, the more immediate demands of their substance use disorder — whether for stimulants and/or opioids — take precedence and can readily become the central focus of their lives. What signals can help a clinician recognize a substance use disorder? How can they differentiate a clinical SUD from intermittent (even though harmful) substance use? What evidence-based treatments should they consider?

Post-test for CME credits: https://elit.dkbmed.com/issues/217/test

Hosted on Acast. See acast.com/privacy for more information.

People living with HIV who’ve had criminal legal involvement face significant challenges that complicate their ability to remain in the HIV care continuum. Many, while incarcerated, have stopped treatment, and once back in the community have been reluctant to resume ART. Why? What are the key drivers behind their disengagement from care? What can clinicians do to encourage these patients to return to treatment? What strategies have been tried, and what’s been shown to work? What does the evidence say?

Post-test for CME credits: https://elit.dkbmed.com/issues/213/test

Hosted on Acast. See acast.com/privacy for more information.

Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.

Post-test for CME credits: https://elit.dkbmed.com/issues/206/test

Hosted on Acast. See acast.com/privacy for more information.